Results 101 to 110 of about 12,413,959 (307)

Cost Analysis of Radioactive Versus Arthroscopic Synovectomy in Haemophilia: A Brazilian Modelling Approach

Haemophilia, EarlyView.
ABSTRACT Introduction Radioactive synovectomy (RSO) is an alternative to arthroscopic synovectomy (AR), for treating synovitis. RSO reduces the number of hemarthroses, being less invasive and less costly. Objective To analyse the costs of RSO compared to AR in the treatment of patients with haemophilia in Brazil, using real‐world data (RSO) and ...
Sylvia Thomas, Mariana Battazza, Vinicius Bednarczuk de Oliveira, Indianara Galhardo, Sergio Augusto Lopes de Souza   +4 more
wiley   +1 more source

HAEMFIX: Impact of Switching From SHL‐FIX to EHL‐FIX in Patients With Haemophilia B

Haemophilia, EarlyView.
ABSTRACT Introduction Haemophilia B is an X‐linked recessive bleeding disorder caused by coagulation factor IX (FIX) deficiency. Treatment involves intravenous replacement of FIX. Recently, extended half‐life (EHL) FIX products have been introduced alongside standard half‐life (SHL) products to optimize therapy. Aim This study evaluated bleeding rates,
Jasmin Lonardi, Susan Halimeh, Sylvia von Mackensen, Lisa Kleinlein, Juliet Fleischer, Henri Funk, Julia Hölz, Johannes Holzapfel, Sabrina Juranek, Victoria Lieftüchter, Christoph Bidlingmaier, Martin Olivieri   +11 more
wiley   +1 more source

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

Haemophilia, 2015
rIX‐FP is a coagulation factor IX (recombinant), albumin fusion protein with more than fivefold half‐life prolongation over other standard factor IX (FIX) products available on the market.
U. Martinowitz, T. Lissitchkov, A. Lubetsky, G. Jotov, Tami Barazani-Brutman, Christine Voigt, Iris Jacobs, T. Wuerfel, Elena Santagostino   +8 more
semanticscholar   +1 more source

F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project [PDF]

, 2023
Veerle Labarque, Maria Elisa Mancuso, Mutlu Kartal‐Kaess, Rolf Ljung, Torben Stamm Mikkelsen, Nadine G. Andersson   +5 more
openalex   +1 more source

Elucidating the Molecular Basis in a Cohort of Patients With Combined Bleeding Tendencies and Joint Hypermobility Manifestations

Haemophilia, EarlyView.
ABSTRACT Background In patients with unexplained bleeding and normal haemostatic parameters, heritable disorders of connective tissue (HDCT) may be an underlying cause due to vascular fragility, as observed in Ehlers–Danlos syndrome (EDS) or Marfan syndrome (MS). This study aims to investigate the molecular profile of patients with joint hypermobility (
Perla Bandini, Nina Borràs, Carme Altisent, Judith Sánchez‐Raya, Laura Martin‐Fernandez, Iris Garcia‐Martínez, Natàlia Comes, Lorena Ramírez, Marta Martorell, Carlos Hobeich, Francisco Vidal, Irene Corrales   +11 more
wiley   +1 more source

Development of a patient-reported outcomes tool to monitor changes in joint health and wellbeing for young people with haemophilia B

The Journal of Haemophilia Practice
Early detection of joint bleeds is challenging yet critical for preserving joint health among individuals with haemophilia. This work explored early indicators of joint bleeds and young people with haemophilia B (YPwHB) self-monitoring practices to ...
Bladen Melanie, McDonagh Janet, McLaughlin Paul, Gooding Richard, Holder Kerry-Ann, Thind Sharon, Klooster Brittany, Shields Alan, Turner-Bowker Diane M., Chatterton Kaitlin, Leso Allison, Volpi Connor, Sivasubramaniyam Sujan, Abulizi Jiawula, Khan Nisa   +14 more
doaj   +1 more source

The impact of severe haemophilia and the presence of target joints on health-related quality-of-life

Health and Quality of Life Outcomes, 2018
Background Joint damage remains a major complication associated with haemophilia and is widely accepted as one of the most debilitating symptoms for persons with severe haemophilia.
Jamie O’Hara, Shaun Walsh, Charlotte Camp, Giuseppe Mazza, Liz Carroll, Christina Hoxer, Lars Wilkinson   +6 more
doaj   +1 more source

Efficacy and safety of the B‐domain‐deleted TQG202 for on‐demand treatment in moderate and severe haemophilia A patients: A multicentre, single‐arm trial [PDF]

, 2023
Zimin Sun, Yaming Xi, Wei Liu, Linhua Yang, Xuefeng Wang, Cheng‐Hao Jin, Haifei Jia, Lei Zhang   +7 more
openalex   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source

Detection of known haemophilia B mutations and carrier testing by microarray [PDF]

, 2005
Kaimin Chan, Werasak Sasanakul, Gillian Mellars, Ampaiwan Chuansumrit, David J. Perry, Christine A. Lee, Man-Sim Wong, T. P. T. Chan, Vivian Chan   +8 more
openalex   +1 more source